Market Place
Sourcing Support
Zymfentra® Coverage Increases with Top 3 PBM Partnership
31 Oct 2024 //
PR NEWSWIRE
Celltrion Presents Analysis Of Liberty Studies For Zymfentra®
29 Oct 2024 //
PR NEWSWIRE
Celltrion Presents 2-Year Findings For Infliximab (CT-P13 SC) In IBD
15 Oct 2024 //
BUSINESSWIRE
ZYMFENTRA Demonstrates 2-Year Crohn`s, UC Efficacy, Safety Profile
21 May 2024 //
PR NEWSWIRE
Celltrion USA, Express Scripts Deal For ZYMFENTRA™ & Autoimmune Therapies
28 Apr 2024 //
PR NEWSWIRE
Advanced Infliximab Model Now Available from DoseMe
15 Mar 2024 //
BUSINESSWIRE
Celltrion presents new two-year data for subcutaneous infliximab (CT-P13 SC)
23 Feb 2024 //
BUSINESSWIRE
Lynx.MD Leveraged for Study on Infliximab Optimization for IBD to be Presented
17 Jan 2024 //
ACCESSWIRE
Pfizer`s Biologic IIxifi (Infliximab) Receives Approval in the U.S.
26 Dec 2023 //
FDA
Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA
23 Oct 2023 //
BUSINESSWIRE
Celltrion`s Biologic Zymfentra (infliximab) Receives Approval in the U.S.
20 Oct 2023 //
FDA
Data Presented Support the Potential of Celltrion’s Infliximab CT-P13
16 Oct 2023 //
BUSINESSWIRE
J&J finalizes $25M settlement,laying Remicade antitrust allegations to rest
21 Mar 2023 //
ENDPTS
J&J finalizes $25M settlement, laying Remicade antitrust allegations to rest
18 Mar 2023 //
ENDPTS
Celltrion submits application for CT-P13 SC to FDA
22 Dec 2022 //
PHARMAFILE
SGS’s Quay Pharma Collaborates to Develop New Oral Medicine
07 Aug 2022 //
PRESS RELEASE
NIH-led Covid-19 trial shows immune modulator drugs boost survival
18 Jul 2022 //
CLINICALTRIALSARENA
Immune modulator drugs improves survival for people hospitalised with COVID-19
03 Jun 2022 //
EXPRESS PHARMA
Bristol Myers, J&J drugs reduce COVID death rates in NIH study
03 Jun 2022 //
REUTERS
New Data Show Greater Improvements in Outcomes with Subcutaneous Infliximab
31 May 2022 //
BUSINESSWIRE
SC Infliximab Superior to IV Dosage in Patients With CD, UC
19 Feb 2022 //
CENTERFORBIOSIMILARS
High Infliximab Trough Levels Associated With Low Risk of Relapse on Infliximab
18 Feb 2022 //
BUSINESSWIRE
Health Canada Issues Recall of Buhlmann Laboratories` Quantum Blue Anti-Infliximab
17 Feb 2022 //
HEALTH CANADA
Takeda, Moderna and more—Fierce Pharma Asia
08 Oct 2021 //
FIERCEPHARMA
Centocor `s Remicade Receives Supplimental Approval in U.S
07 Oct 2021 //
FDA
Biosimilar drugs gain ground in U.S.
21 Sep 2021 //
STATNEWS
J&J, Amgen and Roche face growing biosimilar competition
12 Aug 2021 //
FIERCEPHARMA
WHO-led trial to study three anti-inflammatory drugs for COVID-19 patients
12 Aug 2021 //
REUTERS
A giant trial of COVID-19 treatments is restarting
06 Aug 2021 //
SCIENCEMAG
Baysient Launches Digital TDM App for Fast, Personalized Infliximab Dosing
29 Jun 2021 //
PR NEWSWIRE
NICE Decision On Arthritis Opens Door For Biosimilars In England
16 Jun 2021 //
PINKSHEET
New Report Shows Biosimilars Significantly Lowered Prices of All Biologics
16 Jun 2021 //
FIRSTWORDPHARMA
Children with severe MIS-C do better when treated initially with IVIG & steroids
16 Jun 2021 //
PRNEWSWIRE
NICE recommends several treatment options to help thousands with moderate RA
10 Jun 2021 //
NICE
Biogen Welcomes NICE Announcement on TA375 in Moderate Rheumatoid Arthritis
01 Jun 2021 //
GLOBENEWSWIRE
Celltrion Healthcare receives positive CHMP opinion for subcutaneous
31 Mar 2021 //
BUSINESSWIRE
Grifols launches patient point-of-care system for monitoring infliximab
18 Mar 2021 //
PRESS RELEASE
Egis Pharma Registers First Blood-based CE IVD Precision Medicine Tool
16 Mar 2021 //
MEDINDIA
Meta-analysis Finds Nonsignificant Differences Between Infliximab Biosimilars
02 Mar 2021 //
BIGMOLECULEWATCH
Vedolizumab Improves Immunotherapy-Related Diarrhea, Colitis Better
28 Oct 2020 //
FIRSTWORLDPHARMA
Samsung Bioepis Announces First Real-World Data on RENFLEXIS® (infliximab-abda)
26 Oct 2020 //
GLOBENEWSWIRE
ICER criticizes cost of 8 targeted immune modulators for UC
15 Sep 2020 //
ENDPOINTS
EC Grants Marketing Authorization for Remsima
29 Jul 2020 //
PHARMTECH
Celltrion`s infliximab biosimilar Remsima secures European approval in five indications
28 Jul 2020 //
PHARMAFILE
European Commission grants marketing authorisation of infliximab
27 Jul 2020 //
BIOSPACE
Namilumab and Infliximab selected for CATALYST trial in UK
11 Jun 2020 //
CLINICALTRIALSARENA
Anti-inflammatory and cancer drugs tested in UK as possible COVID-19 therapy
11 Jun 2020 //
ECONOMICTIMES
Celltrion Healthcare showcases positive 1-year data and budget impact analysis
03 Jun 2020 //
BUSINESSWIRE
COVID-19 Delaying Rare Disease and Gene Therapy Trials, Pharma Execs Say
28 May 2020 //
HEMOPHILIANEWSTODAY
Centocor`s Remicade (Infliximab) Receives Supplemental Approval in US
18 May 2020 //
FDA
Celltrion’s Remsima SC launches in Netherlands
07 May 2020 //
KOREAHERALD
Recent Study Examines the Influence of Institutional Incentives of Biosimilars
04 May 2020 //
BIGMOLECULEWATCH
Pfizer v. J&J Remicade Antitrust Trial Deadlines Extended Due to COVID-19
10 Apr 2020 //
BIGMOLECULEWATCH
Subcutaneous Remsima launched in UK
02 Mar 2020 //
PHARMATIMES
J&J gave free services to docs to boost scripts: whistleblower
20 Feb 2020 //
FIERCE PHARMA
Celltrion Healthcare showcases +ve 1Y result for novel formulation of infliximab
14 Feb 2020 //
BUSINESSWIRE
